{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T05:40:28Z","timestamp":1773898828171,"version":"3.50.1"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["2023-ZDLSF-15"],"award-info":[{"award-number":["2023-ZDLSF-15"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270715"],"award-info":[{"award-number":["82270715"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170722"],"award-info":[{"award-number":["82170722"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejim.2025.106445","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T19:36:57Z","timestamp":1754681817000},"page":"106445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Charting the future of AL amyloidosis: Diagnostic advancements, prognostic insights, and therapeutic challenges"],"prefix":"10.1016","volume":"142","author":[{"given":"Xiayin","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiecong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanting","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changhao","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhichun","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiren","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejim.2025.106445_bib0001","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ajh.27177","article-title":"Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment","volume":"99","author":"Gertz","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0002","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ejim.2025.106445_bib0003","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.mayocp.2021.03.012","article-title":"Treatment of AL amyloidosis: mayo stratification of myeloma and risk-adapted therapy (mSMART) Consensus Statement 2020 update","volume":"96","author":"Muchtar","year":"2021","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.6004\/jnccn.2022.7077","article-title":"Immunoglobulin light chain amyloidosis: diagnosis and risk assessment","volume":"21","author":"Zanwar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-024-01040-8","article-title":"Timing and co-occurrence of symptoms prior to a diagnosis of light chain (AL) amyloidosis","volume":"14","author":"Singh","year":"2024","journal-title":"Blood Cancer J"},{"issue":"18","key":"10.1016\/j.ejim.2025.106445_bib0006","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ejim.2025.106445_bib0007","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ejim.2025.106445_bib0008","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/ajh.27179","article-title":"Reduced early mortality with Daratumumab-based frontline therapy inAL amyloidosis: a retrospective cohort study","volume":"99","author":"Chakraborty","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.ejim.2025.106445_bib0009","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/13506129.2024.2406845","article-title":"Refining prognostication in systemic AL amyloidosis: limited value of dFLC","volume":"31","author":"Khwaja","year":"2024","journal-title":"Amyloid"},{"key":"10.1016\/j.ejim.2025.106445_bib0010","first-page":"1","article-title":"Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies","author":"Theodorakakou","year":"2025","journal-title":"Amyloid"},{"key":"10.1016\/j.ejim.2025.106445_bib0011","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024015528","article-title":"Predictive value of free light chain burden in patients with AL amyloidosis treated with Bortezomib-based regimens","author":"Saunders","year":"2025","journal-title":"Blood advances"},{"issue":"5","key":"10.1016\/j.ejim.2025.106445_bib0012","first-page":"1598","article-title":"Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1275 patients","volume":"109","author":"Khwaja","year":"2024","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.ejim.2025.106445_bib0013","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0014","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-023-00789-8","article-title":"The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018","volume":"13","author":"Palladini","year":"2023","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.ejim.2025.106445_bib0015","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bjh.16094","article-title":"Lessons in long term survival from AL amyloidosis","volume":"187","author":"Sloan","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0016","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12882-022-02752-4","article-title":"Value of repeat renal biopsy in the evaluation of AL amyloidosis patients lacking renal response despite of complete hematologic remission: a case report and literature review","volume":"23","author":"Zhang","year":"2022","journal-title":"BMC Nephrol"},{"issue":"11","key":"10.1016\/j.ejim.2025.106445_bib0017","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.clml.2017.06.004","article-title":"Primary amyloidosis with renal involvement: outcomes in 77 consecutive patients at a single center","volume":"17","author":"Wong","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.ejim.2025.106445_bib0018","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/s41375-024-02243-5","article-title":"Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures","volume":"38","author":"Zanwar","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2025.106445_bib0019","article-title":"Blisters as a primary manifestation of systemic amyloidosis","author":"Zhao","year":"2024","journal-title":"Int. J. Dermatol."},{"issue":"6","key":"10.1016\/j.ejim.2025.106445_bib0020","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1177\/00031348211050834","article-title":"Immunoglobulin light chain amyloidosis presenting as inferior vena cava thrombosis","volume":"89","author":"Axentiev","year":"2023","journal-title":"Am Surg"},{"issue":"51","key":"10.1016\/j.ejim.2025.106445_bib0021","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028267","article-title":"Muscle involvement with pseudohypertrophy in systemic light chain amyloidosis: case report","volume":"100","author":"Draghici","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0022","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/s13256-024-04774-y","article-title":"Light-chain amyloidosis with dysphagia as the main symptom: a case report","volume":"18","author":"Ai","year":"2024","journal-title":"J Med Case Rep"},{"issue":"7","key":"10.1016\/j.ejim.2025.106445_bib0023","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s11739-023-03284-x","article-title":"An unusual case of AL amyloidosis presenting as alopecia and nail changes","volume":"18","author":"Bnaya","year":"2023","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.ejim.2025.106445_bib0024","article-title":"Axillary lymphadenopathy as an initial presentation of systemic amyloidosis: a case report and literature review","volume":"10","author":"Kumar","year":"2022","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"12","key":"10.1016\/j.ejim.2025.106445_bib0025","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-019-0263-z","article-title":"Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement","volume":"9","author":"Murray","year":"2019","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.ejim.2025.106445_bib0026","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.ejim.2025.106445_bib0027","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","article-title":"Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains","volume":"48","author":"Katzmann","year":"2002","journal-title":"Clin. Chem."},{"issue":"6","key":"10.1016\/j.ejim.2025.106445_bib0028","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2215\/CJN.02290508","article-title":"Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease","volume":"3","author":"Hutchison","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.ejim.2025.106445_bib0029","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study","volume":"12","author":"Long","year":"2022","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.ejim.2025.106445_bib0030","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(22)00069-2","article-title":"Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study","volume":"9","author":"El-Khoury","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0031","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/bjh.14205","article-title":"Natural history of amyloidosis isolated to fat and bone marrow aspirate","volume":"179","author":"Chakraborty","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.ejim.2025.106445_bib0032","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/ajh.27666","article-title":"Waldenstr\u00f6m Macroglobulinemia: 2025 update on diagnosis, risk stratification, and management","volume":"100","author":"Gertz","year":"2025","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.ejim.2025.106445_bib0033","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/jjco\/hyy202","article-title":"Prevalence and clinical implications of t(11;14) in patients with amyloid light-chain amyloidosis with or without concurrent multiple myeloma","volume":"49","author":"Kobayashi","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.ejim.2025.106445_bib0034","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1182\/bloodadvances.2018023200","article-title":"Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma","volume":"2","author":"Bochtler","year":"2018","journal-title":"Blood advances"},{"issue":"7","key":"10.1016\/j.ejim.2025.106445_bib0035","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/leu.2016.369","article-title":"Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category","volume":"31","author":"Muchtar","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2025.106445_bib0036","article-title":"Feasibility of a biomarker-based screening for pre-SymptomaticAL amyloidosis in patients with intermediate\/high-RiskMGUS","author":"Mangiacavalli","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0037","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1038\/s41467-021-23880-9","article-title":"Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity","volume":"12","author":"Garofalo","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejim.2025.106445_bib0038","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-024-06015-0","article-title":"Using machine learning approaches to develop a fast and easy-to-perform diagnostic tool for patients with light chain amyloidosis: a retrospective real-world study","author":"Liu","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejim.2025.106445_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.973760","article-title":"Alterations of the gut microbiota in patients with immunoglobulin light chain amyloidosis","volume":"13","author":"Yan","year":"2022","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.ejim.2025.106445_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102860","article-title":"Artificial intelligence-enhanced electrocardiogram for the diagnosis of cardiac amyloidosis: a systemic review and meta-analysis","volume":"49","author":"Khan","year":"2024","journal-title":"Curr Probl Cardiol"},{"issue":"2","key":"10.1016\/j.ejim.2025.106445_bib0041","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2967\/jnumed.111.102053","article-title":"In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. Journal of nuclear medicine : official publication","volume":"54","author":"Antoni","year":"2013","journal-title":"Society of Nuclear Medicine"},{"issue":"7","key":"10.1016\/j.ejim.2025.106445_bib0042","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00259-019-04290-y","article-title":"Detection of cardiac amyloidosis with (18)F-florbetaben-PET\/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy","volume":"46","author":"Kircher","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"10.1016\/j.ejim.2025.106445_bib0043","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjh.16112","article-title":"A risk stratification for systemic immunoglobulin light-chain amyloidosis with renal involvement","volume":"187","author":"Li","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"16","key":"10.1016\/j.ejim.2025.106445_bib0044","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.21037\/atm-21-4033","article-title":"A prognostic staging system for light-chain amyloidosis using hepatic and renal indicator data from 1064 Chinese patients","volume":"9","author":"Yan","year":"2021","journal-title":"Ann Transl Med"},{"issue":"9","key":"10.1016\/j.ejim.2025.106445_bib0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16091689","article-title":"A simple frailty score predicts survival and early mortality in systemic AL amyloidosis","volume":"16","author":"R\u00edos-Tamayo","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.ejim.2025.106445_bib0046","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s11739-024-03621-8","article-title":"Advancing precision medicine in immunoglobulin light-chain amyloidosis: a novel prognostic model incorporating multi-organ indicators","volume":"19","author":"Xing","year":"2024","journal-title":"Intern Emerg Med"},{"issue":"11","key":"10.1016\/j.ejim.2025.106445_bib0047","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/ajh.27472","article-title":"Machine-learning based subgroups of AL amyloidosis and cumulative incidence of mortality and end stage kidney disease","volume":"99","author":"Anand","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"15","key":"10.1016\/j.ejim.2025.106445_bib0048","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ejim.2025.106445_bib0049","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ajh.24738","article-title":"Renal outcomes in patients with AL amyloidosis: prognostic factors, renal response and the impact of therapy","volume":"92","author":"Kastritis","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejim.2025.106445_bib0050","doi-asserted-by":"crossref","DOI":"10.1007\/s11255-024-04182-7","article-title":"Enhancing prognostic guidance in renal light-chain amyloidosis: a new staging system incorporating pathological characters","author":"Xing","year":"2024","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"10.1016\/j.ejim.2025.106445_bib0051","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/13506129.2017.1360272","article-title":"Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis","volume":"24","author":"Rubinstein","year":"2017","journal-title":"Amyloid"},{"issue":"3","key":"10.1016\/j.ejim.2025.106445_bib0052","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/ckj\/sfaa019","article-title":"Renal amyloidosis: validation of a proposed histological scoring system in an independent cohort","volume":"14","author":"Hoelbeek","year":"2021","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0053","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","article-title":"Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group","volume":"30","author":"Wechalekar","year":"2023","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0054","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/13506129.2019.1672650","article-title":"The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis","volume":"27","author":"Angel-Korman","year":"2020","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0055","article-title":"Healthcare resource utilisation and costs associated with AL amyloidosis: a retrospective matched cohort study","volume":"14","author":"Shen","year":"2024","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ejim.2025.106445_bib0056","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/13506129.2022.2137400","article-title":"Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases","volume":"30","author":"Dispenzieri","year":"2023","journal-title":"Amyloid"},{"issue":"5","key":"10.1016\/j.ejim.2025.106445_bib0057","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/j.clml.2024.01.013","article-title":"Healthcare resource utilization and cost-of-illness in systemic light chain (AL) amyloidosis in Europe: results from the real-world, retrospective EMN23 study","volume":"24","author":"Jaccard","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2021.2002841","article-title":"Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines","volume":"29","author":"Sanchorawala","year":"2022","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0059","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejim.2025.106445_bib0060","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/13506129.2022.2164488","article-title":"Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study","volume":"30","author":"Kumar","year":"2023","journal-title":"Amyloid"},{"issue":"5","key":"10.1016\/j.ejim.2025.106445_bib0061","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/bjh.18733","article-title":"First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy","volume":"201","author":"Chakraborty","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"25","key":"10.1016\/j.ejim.2025.106445_bib0062","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1182\/blood.2024025899","article-title":"Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy","volume":"144","author":"Chakraborty","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0063","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12935-022-02635-6","article-title":"Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis","volume":"22","author":"Sun","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"3","key":"10.1016\/j.ejim.2025.106445_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2023.100953","article-title":"Daratumumab plus Bortezomib and dexamethasone in newly diagnosed systemic light chain amyloidosis","volume":"47","author":"Kennedy","year":"2023","journal-title":"Curr Probl Cancer"},{"issue":"7","key":"10.1016\/j.ejim.2025.106445_bib0065","first-page":"2355","article-title":"Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study","volume":"109","author":"Shen","year":"2024","journal-title":"Haematologica (Roma)"},{"issue":"18","key":"10.1016\/j.ejim.2025.106445_bib0066","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.2019003633","article-title":"Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria","volume":"135","author":"Kimmich","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0067","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/bjh.19529","article-title":"Response rates to second-line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed\/refractory light chain amyloidosis (AL) after initial Bortezomib-based regime","volume":"205","author":"Bomsztyk","year":"2024","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.ejim.2025.106445_bib0068","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1002\/ajh.26191","article-title":"Daratumumab, lenalidomide, and dexamethasonein systemiclight-chain amyloidosis: high efficacy, relevant toxicity and main adverse effect of gain 1q21","volume":"96","author":"Kimmich","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.ejim.2025.106445_bib0069","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clml.2019.10.019","article-title":"Dual monoclonal antibody therapy in patients with systemic AL amyloidosis and cardiac involvement","volume":"20","author":"Godara","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ejim.2025.106445_bib0070","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.20021","article-title":"Outcomes of daratumumab-bortezomib-thalidomide-dexamethasone in treatment-naive systemic AL amyloidosis","author":"Khwaja","year":"2025","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejim.2025.106445_bib0071","article-title":"Case report: light-chain amyloidosis responsive to selinexor in combination with daratumumab and dexamethasone (SDd) therapy","volume":"11","author":"Long","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0072","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ajh.26399","article-title":"Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab","volume":"97","author":"Szalat","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.ejim.2025.106445_bib0073","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41375-018-0262-2","article-title":"Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis","volume":"33","author":"Abeykoon","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ejim.2025.106445_bib0074","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/10428194.2020.1850717","article-title":"Daratumumab is safe and induces a rapid hematological response in light-chain amyloidosis with severe cardiac impairment","volume":"62","author":"Gounot","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.ejim.2025.106445_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100065","article-title":"First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience","volume":"6","author":"Jeryczynski","year":"2021","journal-title":"ESMO open"},{"issue":"2","key":"10.1016\/j.ejim.2025.106445_bib0076","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/ejh.13535","article-title":"Daratumumab for relapsed AL amyloidosis-when cumulative real-world data precedes clinical trials: a multisite study and systematic literature review","volume":"106","author":"Shragai","year":"2021","journal-title":"Eur. J. Haematol."},{"issue":"3","key":"10.1016\/j.ejim.2025.106445_bib0077","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/bjh.16282","article-title":"Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population","volume":"188","author":"Van de Wyngaert","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.ejim.2025.106445_bib0078","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis","volume":"130","author":"Kaufman","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejim.2025.106445_bib0079","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bjh.15455","article-title":"Daratumumab proves safe and highly effective in AL amyloidosis","volume":"185","author":"Khouri","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.ejim.2025.106445_bib0080","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/13506129.2020.1730791","article-title":"Treatment with daratumumab in patients with relapsed\/refractory AL amyloidosis: a multicentric retrospective study and review of the literature","volume":"27","author":"Lecumberri","year":"2020","journal-title":"Amyloid"},{"issue":"18","key":"10.1016\/j.ejim.2025.106445_bib0081","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.2019004436","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study","volume":"135","author":"Sanchorawala","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0082","article-title":"Serum free light chain level-based and non-fixed cycle daratumumab treatment strategy for patients with light chain amyloidosis","volume":"57","author":"Li","year":"2025","journal-title":"Ann. Med."},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0083","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/13506129.2021.1978423","article-title":"Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis","volume":"29","author":"Rivera Duarte","year":"2022","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0084","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2418339","article-title":"Maintenance therapy promotes profound organ and haematologic response in light-chain amyloidosis patients not undergoing autologous stem cell transplantation","volume":"56","author":"Wang","year":"2024","journal-title":"Ann. Med."},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.6004\/jnccn.2022.7092","article-title":"Individualized approach to management of light chain amyloidosis","volume":"21","author":"Palladini","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.ejim.2025.106445_bib0086","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/bjh.18216","article-title":"A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosis","volume":"198","author":"Ravichandran","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejim.2025.106445_bib0087","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.19766","article-title":"Factors impeding organ recovery despite a deep haematological response in patients with systemic AL amyloidosis","author":"Staron","year":"2024","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.ejim.2025.106445_bib0088","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1200\/JCO.22.00643","article-title":"Graded cardiac response criteria for patients with systemic light chain amyloidosis","volume":"41","author":"Muchtar","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ejim.2025.106445_bib0089","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1001\/jamaoncol.2024.2629","article-title":"Graded organ response and progression criteria for kidney immunoglobulin light chain amyloidosis","volume":"10","author":"Muchtar","year":"2024","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ejim.2025.106445_bib0090","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-020-0306-5","article-title":"A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis","volume":"10","author":"Sidana","year":"2020","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.ejim.2025.106445_bib0091","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1080\/10428194.2021.1885665","article-title":"Validation of the composite organ and hematologic response model for prognostic prediction in a Chinese light chain amyloidosis cohort","volume":"62","author":"Shen","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.ejim.2025.106445_bib0092","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00432-024-05733-2","article-title":"Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis","volume":"150","author":"Li","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0093","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s10238-024-01511-z","article-title":"Early minimal residual disease eradication in light chain amyloidosis generates deeper and faster cardiac response","volume":"24","author":"Xu","year":"2024","journal-title":"Clin. Exp. Med."},{"issue":"7","key":"10.1016\/j.ejim.2025.106445_bib0094","doi-asserted-by":"crossref","first-page":"E244","DOI":"10.1002\/ajh.26562","article-title":"Impact of bone marrow minimal residual disease status on quality of organ response in systemicAL amyloidosis","volume":"97","author":"Chakraborty","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.ejim.2025.106445_bib0095","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-021-00428-0","article-title":"Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis","volume":"11","author":"Palladini","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.ejim.2025.106445_bib0096","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-021-00511-6","article-title":"Detection of minimal residual disease by next generation sequencing in AL amyloidosis","volume":"11","author":"Sarosiek","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.ejim.2025.106445_bib0097","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/bloodadvances.2019001331","article-title":"Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis","volume":"4","author":"Staron","year":"2020","journal-title":"Blood advances"},{"issue":"6","key":"10.1016\/j.ejim.2025.106445_bib0098","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.26536","article-title":"Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone\u2009\u00b1\u2009daratumumab: results from the ANDROMEDA study","volume":"97","author":"Sanchorawala","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0099","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nature reviews. Disease primers"},{"issue":"2","key":"10.1016\/j.ejim.2025.106445_bib0100","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/bjh.18860","article-title":"Is there a representative quality-of-life questionnaire for patients with AL amyloidosis?-systematic literature review","volume":"202","author":"Bristogiannis","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejim.2025.106445_bib0101","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/PROM.S399658","article-title":"Health-related quality of Life instruments for clinical trials in AL amyloidosis: report from the Amyloidosis Forum HRQOL Working Group","volume":"14","author":"Rizio","year":"2023","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.ejim.2025.106445_bib0102","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1124660","article-title":"Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis","volume":"10","author":"Kharoubi","year":"2023","journal-title":"Frontiers in cardiovascular medicine"},{"issue":"12","key":"10.1016\/j.ejim.2025.106445_bib0103","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jchf.2024.07.007","article-title":"Functional status and quality of life in light-chain amyloidosis: advanced imaging, longitudinal changes, and outcomes","volume":"12","author":"Clerc","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10.1016\/j.ejim.2025.106445_bib0104","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/ejh.14183","article-title":"Development and initial validation of the AL-PROfile patient-reported outcome measure in light chain (AL) amyloidosis","volume":"112","author":"D'Souza","year":"2024","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.ejim.2025.106445_bib0105","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ajh.26866","article-title":"Quality of life and symptoms among patients with relapsed\/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice","volume":"98","author":"Sanchorawala","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejim.2025.106445_bib0106","article-title":"Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis","author":"Wang","year":"2024","journal-title":"Blood Rev."},{"issue":"14","key":"10.1016\/j.ejim.2025.106445_bib0107","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2022019406","article-title":"Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial","volume":"142","author":"Gertz","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejim.2025.106445_bib0108","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood.2023022937","article-title":"Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series","volume":"143","author":"Forgeard","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejim.2025.106445_bib0109","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/ejh.14348","article-title":"Safety and efficacy of Teclistamab in patients with relapsed or RefractoryAL amyloidosis","volume":"114","author":"Stalker","year":"2025","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.ejim.2025.106445_bib0110","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1111\/bjh.19286","article-title":"Real-world efficacy of single-agent belantamab mafodotin in relapsed systemicAL amyloidosis","volume":"204","author":"Khwaja","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejim.2025.106445_bib0111","first-page":"1","article-title":"Belantamab Mafodotin in relapsed\/refractory AL amyloidosis: real-world multi-center experience and review of the literature","author":"Lebel","year":"2024","journal-title":"Acta Haematol."},{"issue":"23","key":"10.1016\/j.ejim.2025.106445_bib0112","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1158\/1078-0432.CCR-22-0637","article-title":"Feasibility of a novel academic BCMA-CART (HBI0101) for the treatment of relapsed and refractory AL amyloidosis","volume":"28","author":"Kfir-Erenfeld","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.ejim.2025.106445_bib0113","article-title":"Efficacy and safety of anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell for the treatment of relapsed and refractory AL amyloidosis","author":"Lebel","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1016\/j.ejim.2025.106445_bib0114","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41408-022-00717-2","article-title":"High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis","volume":"12","author":"Khwaja","year":"2022","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.ejim.2025.106445_bib0115","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s00277-022-04890-z","article-title":"Belantamab mafodotin in patients with relapsed\/refractory AL amyloidosis with myeloma","volume":"101","author":"Zhang","year":"2022","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.ejim.2025.106445_bib0116","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3390\/cancers15061710","article-title":"Venetoclax in relapse\/refractory AL amyloidosis\u2014A multicenter international retrospective real-world study","volume":"15","author":"Lebel","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ejim.2025.106445_bib0117","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis","volume":"11","author":"Premkumar","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.ejim.2025.106445_bib0118","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1007\/s00277-024-05901-x","article-title":"Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression","volume":"103","author":"Rieger","year":"2024","journal-title":"Ann. Hematol."},{"issue":"3","key":"10.1016\/j.ejim.2025.106445_bib0119","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjh.17380","article-title":"Venetoclax induces profound and sustained responses in patients with relapsed\/refractory light-chain amyloidosis","volume":"193","author":"Pasquer","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"13","key":"10.1016\/j.ejim.2025.106445_bib0120","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1200\/JCO.19.01721","article-title":"Bendamustine with dexamethasone in relapsed\/refractory systemic light-chain amyloidosis: results of a phase II study","volume":"38","author":"Lentzsch","year":"2020","journal-title":"Journal of Clinical Oncology"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525003231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525003231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:26:25Z","timestamp":1772825185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620525003231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":120,"alternative-id":["S0953620525003231"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2025.106445","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Charting the future of AL amyloidosis: Diagnostic advancements, prognostic insights, and therapeutic challenges","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2025.106445","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106445"}}